Latest CellCept News

Biotech's Small Caps Have Stellar January - PR Newswire (press release)

Significant double digit gains from several Companies in the group helped the index post a 16% gain in January. Top performers were Illumina, Inc. (up 52%), Pain Therapeutics Inc. (up 36%), Senomyx Inc. (up 34%) and Aspreva Pharmaceuticals (up 27%). Aspreva benefited from the news that it had received orphan drug status for CellCept, an anti-rejection drug used for patients receiving Heart, kidney and liver transplants. Its shares closed the month at $19.96. Illumina launched new software tools to analyze DNA copy number changes and characterize loss of heterozygosity. These two conditions provide highly informative molecular signposts of Cancer development and progression and offer potential to help researchers discover new diagnostic and therapeutic targets.

CellCept


No Ebay Marketplace Listings Found

More results for CellCept on Google
Google is currently the number one search engine on the net. If you want to find anything on the web related to CellCept then Google is a great place to start.

More results for CellCept on Overture
Overture is the largest partner search engine on the web. If you are interesting in buying a product related to CellCept or obtaining services related to CellCept then Overture is the place to start.

Try Asking about CellCept
Ask.com may produce some results for CellCept that you can not find anywhere else. Ask will also show you more searches related to CellCept and provide an automatic picture search for CellCept

Mortgage Calculator | Debt Consolidation | Loans | Mortgage | Web Advertising